Posting this under the heading it deserves: EMA product information as a primary source Everything below is what sits behind that.
Something about EMA product information does not reconcile and I would like a second pair of eyes before I decide which half is wrong.
Two sources, both reputable, giving figures that cannot both be right unless they are measuring different quantities. My suspicion is that they are, and I cannot see how.
Picking up the opening post: that is the part I would want checked first.
I would call the community position on EMA product information likely rather than established, and I would be comfortable defending that hedge.
Coming back to post #2, because the follow-up matters more than the original answer.
Correcting a stale claim here is more valuable than adding a new one, because the stale claims are what people find first.
If the premise is wrong, everything after it is decoration.
On EMA product information I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.
Since EMA product information keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
I read post #6 twice before replying, because I had assumed the opposite.
Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.
Post #7 answers the question as asked. The question underneath it is different.
The honest answer on EMA product information is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.
Most people get the first two right and then argue about the fourth.
Language versions of the product information are all official and occasionally differ in emphasis. Where a detail matters, reading two is not paranoid.
Two sources, same conclusion, and I could not rule out that one copied the other.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
For what it is worth, the same held on the two occasions I checked.
Understood. Thank you for being specific about the limits of it.
On post #9 — agreed on the reasoning, with one qualification.
Reading this EMA product information thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
Post #13 answers the question as asked. The question underneath it is different.
The number people quote for EMA product information is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.
Reimbursement is decided nationally and varies substantially between member states for the same authorised product.
I would call that likely rather than established.
One caution on EMA product information: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.
Post #17 is right about the mechanism and I think understates the practical bit.
The version of EMA product information that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Picking up post #17: that is the part I would want checked first.
An observation about EMA product information that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Picking up post #18: that is the part I would want checked first.
Members outside the union should note that essentially none of this transfers, including the parts phrased generally.
I have separated what I observed from what I concluded, which does not always happen.
Coming back to post #20, because the follow-up matters more than the original answer.
Where the EMA product information discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
Offering a way to settle EMA product information rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within the noise, the question was not answerable at this precision.
I read post #24 twice before replying, because I had assumed the opposite.
The public assessment report published at authorisation is one of the best free technical documents available on any of these compounds and it is rarely cited here.
I have no interest in any supplier named above.
Post #26 is right about the mechanism and I think understates the practical bit.
I have three months of notes on EMA product information and the honest summary is that the trend is real and the week-to-week numbers are noise. I nearly drew the opposite conclusion from the first fortnight.
The documentation on EMA product information is better than this thread and I say that as someone who has posted in the thread.